Who are Sohonos's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Adapalene Gel, AKLIEF®, Topical Adapalene Gel 0.1%, Adapalene 0,1% cream, Differin 0.3% Topical Gel, TRIFAROTENE.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/palovarotene.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Sohonos — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sohonos (PALOVAROTENE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Retinoid [EPC]. Area: Bone.

marketed Retinoid [EPC] Retinoic acid receptor gamma Bone Small molecule Live · refreshed every 30 min

Target snapshot

Sohonos (PALOVAROTENE) — Ipsen. Sohonos works by blocking the activity of a specific receptor that helps control bone growth.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sohonos TARGET	PALOVAROTENE	Ipsen	marketed	Retinoid [EPC]	Retinoic acid receptor gamma	2023-01-01
Adapalene Gel	Adapalene Gel	Bausch Health Americas, Inc.	marketed	Retinoid	Retinoic acid receptor gamma (RAR-γ)
AKLIEF®	AKLIEF®	Teva Pharmaceuticals USA	marketed		Retinoic acid receptor alpha, Retinoic acid receptor beta, Retinoic acid receptor gamma
Topical Adapalene Gel 0.1%	Topical Adapalene Gel 0.1%	University of Louisville	marketed	Retinoid	Retinoic acid receptor gamma (RARγ)
Adapalene 0,1% cream	Adapalene 0,1% cream	Dr.dr.Irma Bernadette, SpKK (K)	phase 3	Retinoid	Retinoic acid receptor gamma (RARγ)
Differin 0.3% Topical Gel	Differin 0.3% Topical Gel	Aleor Dermaceuticals Limited	phase 3	Retinoid (third-generation)	Retinoic acid receptor gamma (RARγ)
TRIFAROTENE	TRIFAROTENE		marketed	Retinoid [EPC]		2019-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sohonos — Competitive Intelligence Brief. https://druglandscape.com/ci/palovarotene. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing